Ratings by Piper Sandler (Do Kim)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 8/17/2026 | Codexis, Inc. | CDXS | Maintain | Overweight (N/A) |
|
Details | ||
| 8/15/2024 | Codexis, Inc. | CDXS | Maintain | Overweight (N/A) |
|
Details | ||
| 11/6/2023 | Codexis, Inc. | CDXS | Maintain | Overweight (N/A) |
|
Details | ||
| 4/17/2023 | Codexis, Inc. | CDXS | Maintain | Overweight (N/A) |
|
Details | ||
| 3/13/2023 | Travere Therapeutics | TVTX | Maintain | Overweight (N/A) |
|
Details | ||
| 3/8/2023 | Rigel Pharmaceuticals | RIGL | Maintain | Neutral (N/A) |
|
Details | ||
| 2/23/2023 | Ionis Pharmaceuticals | IONS | Maintain | Overweight (N/A) |
|
Details | ||
| 2/21/2023 | Travere Therapeutics | TVTX | Maintain | Overweight (N/A) |
|
Details | ||
| 2/14/2023 | Schrodinger | SDGR | Maintain | Overweight (N/A) |
|
Details | ||
| 2/3/2023 | Gilead Sciences | GILD | Maintain | Overweight (N/A) |
|
Details | ||
| 1/19/2023 | Vertex | VRTX | Maintain | Neutral (N/A) |
|
Details | ||
| 1/19/2023 | Schrodinger | SDGR | Maintain | Overweight (N/A) |
|
Details | ||
| 1/19/2023 | Ionis Pharmaceuticals | IONS | Maintain | Overweight (N/A) |
|
Details | ||
| 1/19/2023 | Gilead Sciences | GILD | Maintain | Overweight (N/A) |
|
Details | ||
| 1/19/2023 | Codexis, Inc. | CDXS | Maintain | Overweight (N/A) |
|
Details | ||
| 1/10/2023 | Travere Therapeutics | TVTX | Maintain | Overweight (N/A) |
|
Details | ||
| 1/6/2023 | TCR2 Therapeutics | TCRR | Maintain | Overweight (N/A) |
|
Details | ||
| 12/14/2022 | Replimune Group | REPL | Maintain | Overweight (N/A) |
|
Details | ||
| 12/12/2022 | Affimed Therapeutics | AFMD | Maintain | Overweight (N/A) |
|
Details | ||
| 10/28/2022 | Gilead Sciences | GILD | Upgrade | Overweight (Neutral) |
70.20 (147.60) |
110.26% | Details | |
| 10/24/2022 | Rigel Pharmaceuticals | RIGL | Maintain | Neutral (N/A) |
|
Details | ||
| 10/17/2022 | Vertex | VRTX | Maintain | Neutral (N/A) |
|
Details | ||
| 10/14/2022 | Travere Therapeutics | TVTX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/17/2022 | Vertex | VRTX | Maintain | Neutral (N/A) |
|
Details | ||
| 8/17/2022 | Rigel Pharmaceuticals | RIGL | Maintain | Neutral (N/A) |
|
Details | ||
| 8/17/2022 | Replimune Group | REPL | Maintain | Overweight (N/A) |
|
Details | ||
| 7/26/2022 | Vertex | VRTX | Maintain | Neutral (N/A) |
|
Details | ||
| 7/26/2022 | Travere Therapeutics | TVTX | Maintain | Overweight (N/A) |
|
Details | ||
| 7/26/2022 | Schrodinger | SDGR | Maintain | Overweight (N/A) |
|
Details | ||
| 7/26/2022 | Ionis Pharmaceuticals | IONS | Maintain | Overweight (N/A) |
|
Details | ||
| 7/26/2022 | Gilead Sciences | GILD | Maintain | Neutral (N/A) |
|
Details | ||
| 7/26/2022 | Exelixis | EXEL | Maintain | Overweight (N/A) |
|
Details | ||
| 7/26/2022 | AbCellera Biologics | ABCL | Maintain | Overweight (N/A) |
|
Details | ||
| 7/15/2022 | Codexis, Inc. | CDXS | Maintain | Overweight (N/A) |
|
Details | ||
| 6/8/2022 | Rigel Pharmaceuticals | RIGL | Downgrade | Neutral (Overweight) |
1.76 (46.96) |
2568.18% | Details | |
| 5/19/2022 | Replimune Group | REPL | Maintain | Overweight (N/A) |
|
Details | ||
| 5/17/2022 | Scholar Rock | SRRK | Maintain | Overweight (N/A) |
|
Details | ||
| 5/17/2022 | Gilead Sciences | GILD | Maintain | Neutral (N/A) |
|
Details | ||
| 5/11/2022 | AbCellera Biologics | ABCL | Maintain | Overweight (N/A) |
|
Details | ||
| 5/6/2022 | Vertex | VRTX | Maintain | Neutral (N/A) |
|
Details | ||
| 4/29/2022 | Gilead Sciences | GILD | Maintain | Neutral (N/A) |
|
Details | ||
| 4/22/2022 | Vertex | VRTX | Maintain | Neutral (N/A) |
|
Details | ||
| 4/11/2022 | Affimed Therapeutics | AFMD | Maintain | Overweight (N/A) |
|
Details | ||
| 4/4/2022 | Gilead Sciences | GILD | Maintain | Neutral (N/A) |
|
Details | ||
| 3/31/2022 | Affimed Therapeutics | AFMD | New Coverage | Overweight (N/A) |
4.45 (0.18) |
-95.96% | Details | |
| 3/31/2022 | Travere Therapeutics | TVTX | New Coverage | Overweight (N/A) |
26.05 (64.86) |
148.98% | Details | |
| 3/31/2022 | Ionis Pharmaceuticals | IONS | New Coverage | Overweight (N/A) |
36.48 (60.80) |
66.67% | Details | |
| 3/31/2022 | Codexis, Inc. | CDXS | New Coverage | Overweight (N/A) |
21.18 (1.60) |
-92.45% | Details | |
| 3/22/2022 | TCR2 Therapeutics | TCRR | Maintain | Overweight (N/A) |
|
Details | ||
| 1/24/2022 | Schrodinger | SDGR | Maintain | Overweight (N/A) |
|
Details | ||
| 1/24/2022 | Gilead Sciences | GILD | Maintain | Neutral (N/A) |
|
Details | ||
| 11/19/2021 | TCR2 Therapeutics | TCRR | New Coverage | Overweight (N/A) |
6.60 (1.48) |
-77.58% | Details | |
| 11/19/2021 | Replimune Group | REPL | New Coverage | Overweight (N/A) |
33.27 (14.81) |
-55.49% | Details | |
| 11/19/2021 | Gilead Sciences | GILD | New Coverage | Neutral (N/A) |
67.46 (147.60) |
118.8% | Details | |
| 11/19/2021 | Exelixis | EXEL | New Coverage | Overweight (N/A) |
17.88 (54.39) |
204.19% | Details | |
| 11/19/2021 | AbCellera Biologics | ABCL | New Coverage | Overweight (N/A) |
14.82 (12.01) |
-18.96% | Details | |
| 11/19/2021 | Vertex | VRTX | Downgrade | Neutral (Overweight) |
188.25 (543.78) |
188.86% | Details | |
| 11/19/2021 | Scholar Rock | SRRK | New Coverage | Overweight (N/A) |
34.34 (56.51) |
64.56% | Details | |
| 11/18/2021 | Schrodinger | SDGR | New Coverage | Overweight (N/A) |
44.45 (19.85) |
-55.34% | Details |
